In a prospective, double-blind study, we have examined the effect of preoperative nabilone on postoperative nausea and vomiting (PONV) The cannabinoids possess several potentially useful therapeutic actions, including antiemetic, analgesic and anxiolytic effects, bronchodilatation and a reduction in intraocular pressure [1, 2] . Nabilone is a synthetic cannabinoid with reported antiemetic effects in patients undergoing cancer chemotherapy [3] [4] [5] . There are no published reports in the medical literature on the use of cannabinoids for the treatment of PONV. The present study was designed to investigate the acceptability of nabilone, given as part of the premedication regimen and its effect on PONV in patients undergoing total abdominal hysterectomy.
The cannabinoids possess several potentially useful therapeutic actions, including antiemetic, analgesic and anxiolytic effects, bronchodilatation and a reduction in intraocular pressure [1, 2] . Nabilone is a synthetic cannabinoid with reported antiemetic effects in patients undergoing cancer chemotherapy [3] [4] [5] . There are no published reports in the medical literature on the use of cannabinoids for the treatment of PONV. The present study was designed to investigate the acceptability of nabilone, given as part of the premedication regimen and its effect on PONV in patients undergoing total abdominal hysterectomy.
METHODS AND RESULTS
After obtaining approval from the local Ethics Committee on Human Research and informed written consent, we studied 60 women, ASA I or II, less than 70 yr of age, undergoing elective total abdominal hysterectomy. Patients with a past history of psychiatric illness, chronic psychiatric or antiemetic medication were excluded.
All patients were allowed clear liquids up to 4 h before operation. Oral diazepam 10 mg was given 90 min before operation, with either nabilone 2 mg or metoclopramide 10 mg in a random sequence.
Thiopentone 3-5 mg kg" 1 was used to induce anaesthesia followed by suxamethonium 1 mg kg" 1 to facilitate tracheal intubation. Anaesthesia was maintained with 66 % nitrous oxide and 1-2 % isoflurane in oxygen. Patients received i.v. papaveretum ("old" formulation containing noscapine: 0.3 mg kg" 1 in divided doses) and rectal diclofenac 100 mg during surgery for postoperative analgesia. Pancuronium O.lmgkg" 1 was used to produce neuromuscular block; residual block was antagonized with neostigmine 2.5 mg and glycopyrronium 0.5 mg.
Patients were given prochlorperazine 12.5 mg i.m., 6-hourly as required, for > 1 episode of vomiting in the recovery room or on the ward and papaveretum 0.1 mg kg" 1 i.v. in recovery or 0.3 mg kg" 1 i.m. 3-hourly in the ward for analgesia at the discretion of a member of the nursing staff. All patients received i.v. lactated Ringer's solution or blood during surgery at the discretion of the (consultant) anaesthetist. I.v. glucose 4% and saline 0.18 % were administered at a rate of approximately 2000 ml 24 h"' after operation until patients tolerated oral fluids.
The anaesthetist, recovery and nursing staff were all blinded to the allocated premedication. The incidence of PONV, and antiemetic and opioid use during the first 24 h after surgery were recorded by nursing staff on one dedicated gynaecological ward. Retching was regarded as vomiting. Patients were interviewed on the first day after operation to determine the levels of PONV and pain, using 10-cm visual analogue scales (minimum 0, maximum 10) during the 24-h period after surgery. Patients were asked about sedation, relaxation or adverse effects after premedication.
An earlier survey of patients undergoing total abdominal hysterectomy in our unit indicated a 70 % incidence of vomiting. Approximately 26-30 patients per group were required to detect a 50 % difference in the incidence of vomiting, with an 80 % power of achieving a statistically significant result at the 5 % (96) level. Data were analysed using the unpaired Student's t test, Mann-Whitney U test or chi-square test with Yates' continuity correction, as appropriate. P < 0.05 was considered statistically significant.
Sixty patients were recruited into the study and data from seven patients (four nabilone, three metoclopramide) were excluded from analysis for non-clinical reasons or incomplete data. The two groups of remaining patients were comparable in age (range 23-67 yr) and weight. There were no significant differences in the incidences of PONV or antiemetic use between the two groups in the recovery room or on the ward (table I) . Papaveretum was administered significantly less frequently in the recovery room to the nabilone group compared with the metoclopramide group; there was no difference between the two groups in the incidence of opioid administration on the ward (table I) .
There were no significant differences between the two groups of patients in the level of PONV or pain, as measured by visual analogue scales (table I). The majority of patients in both groups felt relaxed after premedication and reported that they would have the same premedication again (table 1). One patient (metoclopramide group) spontaneously reported an adverse effect ("dizziness" after premedication); there were no spontaneous or elicited reports of psychotic phenomena in either group. COMMENT We found that nabilone failed to reduce the incidence of PONV compared with metoclopramide and this contrasts with its effectiveness in patients undergoing chemotherapy. This finding might be explained by differences in the mechanisms of postoperative and chemotherapy-induced emesis, or in the mechanisms of action of nabilone and metoclopramide.
Cancer chemotherapeutdc agents may induce vomiting via several different pathways. The effectiveness of dopaminergic antagonists such as metoclopramide suggests that blood-borne drugs and toxins, including chemotherapeutic agents, act directly on the chemoreceptor trigger zone (CTZ) [6] . The complex process of PONV is associated with afferent stimuli from the pharynx, gastrointestinal tract and mediastinum, with input from the cerebral cortex, CTZ, visual centres and the vestibular portion of the eighth cranial nerve [4] . The effectiveness of many dopaminergic, 5-HT 3 , histaminergic and muscarinic-cholinergic receptor antagonists again suggests a central role for the CTZ in the process of PONV. Conventional management of PONV usually includes prophylactic administration of an antagonist for one or more of these receptor sites. The antiemetic mechanism of nabilone is distinct and appears to be related to psychotropic effects in the forebrain, inhibiting the emetic centre via descending neural pathways [2] .
Other potential explanations for the failure of nabilone to reduce the incidence of PONV in our study include an inappropriately small dose or lack of repeated doses. We chose 2 mg in order to avoid adverse reactions; it is possible that the antiemetic action of nabilone is effective only at doses which also result in a high incidence of adverse effects. Inappropriate timing or differences in the route of administration may also explain the inconsistent results obtained by different investigators using metoclopramide as a postoperative antiemetic [4] . It is possible therefore that metoclopramide, as administered in our study, was no more effective than placebo.
The adverse effects of nabilone appear to be doserelated : a single oral dose (1 mg) produced no central nervous or cardiovascular side effects in healthy volunteers, whereas a larger single dose (5 mg) or repeated doses were associated with adverse effects [2] . There were no adverse effects in the nabilone group in our study; however, studies of patients undergoing chemotherapy typically used a larger dose (2 mg, 8-hourly) for several days [5] . It is also interesting to note that the nabilone group required less analgesia in recovery. This finding may have been caused by drowsiness or a genuine analgesic action of nabilone; unfortunately the quality and duration of recovery was not specifically measured in our study.
In summary, we conclude that in the doses used, nabilone is no more effective than metoclopramide as a postoperative antiemetic in women undergoing abdominal hysterectomy. Larger single doses or repeated doses of nabilone may be more effective but would probably result in significant adverse effects.
